Literature DB >> 11206074

Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies.

A M Petros1, D G Nettesheim, Y Wang, E T Olejniczak, R P Meadows, J Mack, K Swift, E D Matayoshi, H Zhang, C B Thompson, S W Fesik.   

Abstract

The three-dimensional structure of the anti-apoptotic protein Bcl-xL complexed to a 25-residue peptide from the death promoting region of Bad was determined using NMR spectroscopy. Although the overall structure is similar to Bcl-xL bound to a 16-residue peptide from the Bak protein (Sattler et al., 1997), the Bad peptide forms additional interactions with Bcl-xL. However, based upon site-directed mutagenesis experiments, these additional contacts do not account for the increased affinity of the Bad 25-mer for Bcl-xL compared to the Bad 16-mer. Rather, the increased helix propensity of the Bad 25-mer is primarily responsible for its greater affinity for Bcl-xL. Based on this observation, a pair of 16-residue peptides were designed and synthesized that were predicted to have a high helix propensity while maintaining the interactions important for complexation with Bcl-xL. Both peptides showed an increase in helix propensity compared to the wild-type and exhibited an enhanced affinity for Bcl-xL.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11206074      PMCID: PMC2144516          DOI: 10.1110/ps.9.12.2528

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  21 in total

1.  Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes.

Authors:  D A Matthews; P S Dragovich; S E Webber; S A Fuhrman; A K Patick; L S Zalman; T F Hendrickson; R A Love; T J Prins; J T Marakovits; R Zhou; J Tikhe; C E Ford; J W Meador; R A Ferre; E L Brown; S L Binford; M A Brothers; D M DeLisle; S T Worland
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death.

Authors:  S W Muchmore; M Sattler; H Liang; R P Meadows; J E Harlan; H S Yoon; D Nettesheim; B S Chang; C B Thompson; S L Wong; S L Ng; S W Fesik
Journal:  Nature       Date:  1996-05-23       Impact factor: 49.962

3.  Helix propagation and N-cap propensities of the amino acids measured in alanine-based peptides in 40 volume percent trifluoroethanol.

Authors:  C A Rohl; A Chakrabartty; R L Baldwin
Journal:  Protein Sci       Date:  1996-12       Impact factor: 6.725

4.  Elucidating the folding problem of helical peptides using empirical parameters. III. Temperature and pH dependence.

Authors:  V Muñoz; L Serrano
Journal:  J Mol Biol       Date:  1995-01-20       Impact factor: 5.469

5.  Elucidating the folding problem of helical peptides using empirical parameters. II. Helix macrodipole effects and rational modification of the helical content of natural peptides.

Authors:  V Muñoz; L Serrano
Journal:  J Mol Biol       Date:  1995-01-20       Impact factor: 5.469

6.  Equilibrium and kinetic inhibition assays based upon fluorescence polarization.

Authors:  W B Dandliker; M L Hsu; J Levin; B R Rao
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

7.  Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity.

Authors:  W Shakespeare; M Yang; R Bohacek; F Cerasoli; K Stebbins; R Sundaramoorthi; M Azimioara; C Vu; S Pradeepan; C Metcalf; C Haraldson; T Merry; D Dalgarno; S Narula; M Hatada; X Lu; M R van Schravendijk; S Adams; S Violette; J Smith; W Guan; C Bartlett; J Herson; J Iuliucci; M Weigele; T Sawyer
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

8.  Side chain and backbone assignments in isotopically labeled proteins from two heteronuclear triple resonance experiments.

Authors:  T M Logan; E T Olejniczak; R X Xu; S W Fesik
Journal:  FEBS Lett       Date:  1992-12-21       Impact factor: 4.124

9.  Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death.

Authors:  E Yang; J Zha; J Jockel; L H Boise; C B Thompson; S J Korsmeyer
Journal:  Cell       Date:  1995-01-27       Impact factor: 41.582

10.  Stereospecific nuclear magnetic resonance assignments of the methyl groups of valine and leucine in the DNA-binding domain of the 434 repressor by biosynthetically directed fractional 13C labeling.

Authors:  D Neri; T Szyperski; G Otting; H Senn; K Wüthrich
Journal:  Biochemistry       Date:  1989-09-19       Impact factor: 3.162

View more
  139 in total

1.  The structure of Bcl-w reveals a role for the C-terminal residues in modulating biological activity.

Authors:  Mark G Hinds; Martin Lackmann; Gretchen L Skea; Penny J Harrison; David C S Huang; Catherine L Day
Journal:  EMBO J       Date:  2003-04-01       Impact factor: 11.598

2.  Structural changes in the BH3 domain of SOUL protein upon interaction with the anti-apoptotic protein Bcl-xL.

Authors:  Emmanuele Ambrosi; Stefano Capaldi; Michele Bovi; Gianmaria Saccomani; Massimiliano Perduca; Hugo L Monaco
Journal:  Biochem J       Date:  2011-09-01       Impact factor: 3.857

3.  A multimeric model for murine anti-apoptotic protein Bcl-2 and structural insights for its regulation by post-translational modification.

Authors:  Venkatarajan S Mathura; Kizhake V Soman; Tushar K Varma; Werner Braun
Journal:  J Mol Model       Date:  2003-08-30       Impact factor: 1.810

4.  Molecular recognition of protein surfaces: high affinity ligands for the CBP KIX domain.

Authors:  Stacey E Rutledge; Heather M Volkman; Alanna Schepartz
Journal:  J Am Chem Soc       Date:  2003-11-26       Impact factor: 15.419

5.  Design and synthesis of type-III mimetics of omega-conotoxin GVIA.

Authors:  J B Baell; S A Forsyth; R W Gable; R S Norton; R J Mulder
Journal:  J Comput Aided Mol Des       Date:  2001-12       Impact factor: 3.686

6.  Bcl-2 homodimerization involves two distinct binding surfaces, a topographic arrangement that provides an effective mechanism for Bcl-2 to capture activated Bax.

Authors:  Zhi Zhang; Suzanne M Lapolla; Matthew G Annis; Mary Truscott; G Jane Roberts; Yiwei Miao; Yuanlong Shao; Chibing Tan; Jun Peng; Arthur E Johnson; Xuejun C Zhang; David W Andrews; Jialing Lin
Journal:  J Biol Chem       Date:  2004-08-09       Impact factor: 5.157

7.  Evidence that inhibition of BAX activation by BCL-2 involves its tight and preferential interaction with the BH3 domain of BAX.

Authors:  Bonsu Ku; Chengyu Liang; Jae U Jung; Byung-Ha Oh
Journal:  Cell Res       Date:  2010-11-09       Impact factor: 25.617

8.  Bcl-2 and Bax interact via the BH1-3 groove-BH3 motif interface and a novel interface involving the BH4 motif.

Authors:  Jingzhen Ding; Zhi Zhang; G Jane Roberts; Mina Falcone; Yiwei Miao; Yuanlong Shao; Xuejun C Zhang; David W Andrews; Jialing Lin
Journal:  J Biol Chem       Date:  2010-06-28       Impact factor: 5.157

9.  Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression.

Authors:  Jianfang Chen; Haibin Zhou; Angelo Aguilar; Liu Liu; Longchuan Bai; Donna McEachern; Chao-Yie Yang; Jennifer L Meagher; Jeanne A Stuckey; Shaomeng Wang
Journal:  J Med Chem       Date:  2012-10-02       Impact factor: 7.446

10.  Dynamical binding of hydrogen-bond surrogate derived Bak helices to antiapoptotic protein Bcl-xL.

Authors:  Ju Bao; Xiao Y Dong; John Z H Zhang; Paramjit S Arora
Journal:  J Phys Chem B       Date:  2009-03-19       Impact factor: 2.991

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.